AngioDynamics, Inc. $ANGO Stake Lowered by Royce & Associates LP

Royce & Associates LP trimmed its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 2.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,921,526 shares of the medical instruments supplier’s stock after selling 48,309 shares during the period. Royce & Associates LP owned 4.57% of AngioDynamics worth $29,553,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of ANGO. Integrated Wealth Concepts LLC bought a new position in AngioDynamics in the second quarter valued at approximately $38,000. Pinnacle Wealth Planning Services Inc. acquired a new stake in AngioDynamics during the 3rd quarter worth $40,000. Legal & General Group Plc bought a new stake in shares of AngioDynamics during the 2nd quarter valued at $45,000. Public Employees Retirement System of Ohio bought a new stake in shares of AngioDynamics during the 2nd quarter valued at $64,000. Finally, State of Wyoming bought a new stake in shares of AngioDynamics during the 2nd quarter valued at $72,000. 89.43% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on ANGO shares. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 price target on shares of AngioDynamics in a research note on Friday, October 9th. HC Wainwright decreased their price objective on AngioDynamics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, October 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Thursday, October 15th. Wall Street Zen lowered AngioDynamics from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Finally, Zacks Research raised AngioDynamics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $19.00.

AngioDynamics Stock Performance

NASDAQ:ANGO traded down $0.11 during trading hours on Friday, hitting $11.87. The stock had a trading volume of 280,801 shares, compared to its average volume of 641,074. AngioDynamics, Inc. has a one year low of $9.39 and a one year high of $16.29. The company has a market cap of $499.13 million, a price-to-earnings ratio of -15.22 and a beta of 0.30. The business’s 50 day moving average is $13.42 and its 200-day moving average is $12.54.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 10.12% and a negative return on equity of 4.49%. The company had revenue of $80.92 million for the quarter, compared to analysts’ expectations of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, sell-side analysts anticipate that AngioDynamics, Inc. will post -0.27 EPS for the current fiscal year.

Insiders Place Their Bets

In other AngioDynamics news, CFO Stephen Trowbridge sold 23,615 shares of AngioDynamics stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $12.27, for a total transaction of $289,756.05. Following the transaction, the chief financial officer directly owned 280,461 shares in the company, valued at approximately $3,441,256.47. The trade was a 7.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 6.00% of the company’s stock.

AngioDynamics Profile

AngioDynamics, Inc. develops, manufactures and markets medical devices used in minimally invasive procedures. Its products are designed for clinicians in areas including vascular access, peripheral vascular disease and oncology. The company’s offerings include vascular access devices such as ports and catheters, as well as technologies used in vascular intervention and cancer treatment. These include the Auryon atherectomy system, which is used to treat certain peripheral arterial conditions, and the NanoKnife System, which uses irreversible electroporation in tumor ablation procedures.